|Articles|November 14, 2018
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Advertisement
In May, the FDA approved erenumab, the first calcitonin gene-related peptide (CGRP) inhibitor for the prevention of migraine in adults. Since then, 2 other CGRP inhibitors have gained approval, providing a new class of drugs for those who suffer from migraine.
This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss the emerging therapy for the condition, which affects 39 million people in the United States.
Log in to listen to the podcast.
Listen above or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Read more:
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
- Trends in RNA Therapeutic Research
September 8th 2025
- The Therapeutic Potential of Circular RNA
September 7th 2025
- CGTLive®’s Weekly Rewind – September 5, 2025
September 5th 2025
Advertisement
Advertisement